Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04583514 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

Study acronym: EAT 2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v7
  2. Study Identification, Study Status, Oversightv6
  3. Enrollment target: 70 to 58
    • Eligibility criteria expanded, about 7 words
    v5
  4. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v4
  5. Re-verified, no change to tracked fieldsv3
  6. Secondary endpoints: details revised at 1 of 2 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the changes and mechanisms of (subQ) adipose tissue expandability that occur as a result of short-term weight gain and to investigate the effects on cardio-metabolic health outcomes. Findings from this study will provide new insight into the dynamics of adipose expansion and remodeling during changes in energy balance and how this may impact future fat tissue function and metabolic health.
Trial Details
NCT Number NCT04583514
Lead Sponsor Pennington Biomedical Research Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Overweight and Obesity, Metabolic Syndrome
Related terms Insulin Resistance, Metabolic Syndrome, Obesity, Overweight
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov